- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03028532
Administration of Clomiphene: Short and Long Term Metabolism in an Anti-Doping Setting
Clomiphene (Clomid) is a drug FDA approved to treat female infertility, however, it is often used by men in an off-label setting to both treat male infertility and in a multitude of sports disciplines to increase performance.
Study Objectives:
- Determine detection windows for clomiphene and its metabolites in urine following a medium-term administration
- Understand the effect of clomiphene administration on luteinizing hormone (LH), follicle-stimulating hormone (FSH), and serum testosterone (T) concentrations in a longitudinal manner
- Identify changes in current steroidal module of Athlete Biological Passport
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84124
- Heidi Jo Hansen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Active males who engage in regular exercise between the ages of 18 and 40 on the day of enrollment
• For this study, regular exercise is defined as: physical activity resulting in an increased heart rate for at least 30 minutes per day, 4-5 days per week.
Exclusion Criteria:
- Individuals outside of the described age range on the day of enrollment
- Individuals who are in a Registered Testing Pool for anti-doping purposes, or individuals who for any reason could be subject to doping control testing
- Individuals who are unwilling or unable to provide blood or urine samples
- Individuals who do not actively exercise
- Individuals with any history of cancer, cardiovascular disease, endocrine abnormalities, infertility, hypoandrogenism, renal disease, hepatic disease, neurologic disease, or any psychiatric history
- Individuals who have previously used anabolic steroids, selective estrogen receptor modulators (SERMs), selective androgen receptor modulators (SARMs), or who are currently using any substances included on the WADA Prohibited List
- History of venous thromboembolic disease (i.e. deep vein thrombosis or pulmonary embolism)
- History of untreated cataracts
- History of intracranial lesions such as pituitary tumors
- Transaminase elevation greater than 3 times the upper limit of normal (ULN)
- Moderate or heavy alcohol intake
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Clomid
All participants will be receiving Clomid and will follow the same study procedures.
|
Participants will self-administer Clomid (50mg oral tablet) once daily for 30 consecutive days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The window of detection for the clomiphene parent compound and metabolites following a 30-day administration will be identified.
Time Frame: Day 30 through end of study participation (minimum, Day 72)
|
◦This will be determined as the amount of time following the final dose (day 30) until clomiphene nor its metabolites are no longer detectable in a urine sample.
|
Day 30 through end of study participation (minimum, Day 72)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of clomiphene administration on serum LH, FSH, and T levels for potential inclusion into a hematological-based longitudinal steroid profile.
Time Frame: Day 30 through end of study participation (minimum, Day 72)
|
A baseline for LH, FSH, and T will be established using the average of serum concentrations calculated from the pre-administration samples from each subject.The change in serum concentrations following administration will be compared against the baseline values.
|
Day 30 through end of study participation (minimum, Day 72)
|
Effect on current steroidal module of Athlete Biological Passport
Time Frame: Day 30 through end of study participation (minimum, Day 72)
|
◦The steroidal module of the Athlete Biological Passport, a statistical model used to identify doping, will be used for data analysis in this study.As stated in the ABP Operating Guidelines, the steroidal compounds described above are considered for the ABP steroidal module in addition to the following ratios: T/E, A/T, A/Etio, 5aAdiol/5βAdiol, and 5aAdiol/E.
Changes in the urinary steroid concentrations and these ratios will be assessed over the course of the study.
|
Day 30 through end of study participation (minimum, Day 72)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stuart Willick, MD, University of Utah
Publications and helpful links
General Publications
- Moskovic DJ, Katz DJ, Akhavan A, Park K, Mulhall JP. Clomiphene citrate is safe and effective for long-term management of hypogonadism. BJU Int. 2012 Nov;110(10):1524-8. doi: 10.1111/j.1464-410X.2012.10968.x. Epub 2012 Mar 28.
- Katz DJ, Nabulsi O, Tal R, Mulhall JP. Outcomes of clomiphene citrate treatment in young hypogonadal men. BJU Int. 2012 Aug;110(4):573-8. doi: 10.1111/j.1464-410X.2011.10702.x. Epub 2011 Nov 1.
- Taylor F, Levine L. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost. J Sex Med. 2010 Jan;7(1 Pt 1):269-76. doi: 10.1111/j.1743-6109.2009.01454.x. Epub 2009 Aug 17.
- Guay AT, Jacobson J, Perez JB, Hodge MB, Velasquez E. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit? Int J Impot Res. 2003 Jun;15(3):156-65. doi: 10.1038/sj.ijir.3900981.
- Niederberger C. Re: outcomes of clomiphene citrate treatment in young hypogonadal men. J Urol. 2013 Mar;189(3):1039. doi: 10.1016/j.juro.2012.11.143. Epub 2013 Jan 22. No abstract available.
- Chandrapal JC, Nielson S, Patel DP, Zhang C, Presson AP, Brant WO, Myers JB, Hotaling JM. Characterising the safety of clomiphene citrate in male patients through prostate-specific antigen, haematocrit, and testosterone levels. BJU Int. 2016 Dec;118(6):994-1000. doi: 10.1111/bju.13546. Epub 2016 Jun 24.
- Helo S, Mahon J, Ellen J, Wiehle R, Fontenot G, Hsu K, Feustel P, Welliver C, McCullough A. Serum levels of enclomiphene and zuclomiphene in men with hypogonadism on long-term clomiphene citrate treatment. BJU Int. 2017 Jan;119(1):171-176. doi: 10.1111/bju.13625. Epub 2016 Sep 11.
- Patel DP, Brant WO, Myers JB, Presson AP, Johnstone EB, Dorais JA, Aston KI, Carrell DT, Hotaling JM. The safety and efficacy of clomiphene citrate in hypoandrogenic and subfertile men. Int J Impot Res. 2015 Nov-Dec;27(6):221-4. doi: 10.1038/ijir.2015.21. Epub 2015 Aug 20.
- Roth LW, Ryan AR, Meacham RB. Clomiphene citrate in the management of male infertility. Semin Reprod Med. 2013 Jul;31(4):245-50. doi: 10.1055/s-0033-1345271. Epub 2013 Jun 17.
- Miller GD, Moore C, Nair V, Hill B, Willick SE, Rogol AD, Eichner D. Hypothalamic-Pituitary-Testicular Axis Effects and Urinary Detection Following Clomiphene Administration in Males. J Clin Endocrinol Metab. 2019 Mar 1;104(3):906-914. doi: 10.1210/jc.2018-01159.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Estrogen Antagonists
- Reproductive Control Agents
- Fertility Agents, Female
- Fertility Agents
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Clomiphene
- Enclomiphene
- Zuclomiphene
Other Study ID Numbers
- 97194
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sports Drug Abuse
-
University of CopenhagenActive, not recruitingSports Drug AbuseDenmark
-
Association Athletes For TransparencyPartnership for Clean Competition; University of Milan School of Medicine; Centre... and other collaboratorsUnknown
-
Norwegian School of Sport SciencesWithdrawn
-
Lund UniversityCompletedIntravenous Drug Abuse, S Aureus Colonization
-
Duke UniversityCompletedHealth Behavior | Opioid Use, Unspecified | Benzodiazepine Abuse | Prescription Drug Abuse (Not Dependent) | Benzodiazepine Dependent | Prescription Drug Abuse and DependencyUnited States
-
Eli Lilly and CompanyCompletedPrescription Drug Abuse (Not Dependent) | Recreational Drug UseUnited States
-
Boston UniversityNational Institute on Drug Abuse (NIDA)WithdrawnIntravenous Drug Abuse
-
National Health Promotion Associates, Inc.UnknownSubstance Use | Substance Abuse | Prescription Drug Abuse (Not Dependent)United States
-
INSYS Therapeutics IncCompletedDrug Abuse, MedicationCanada
-
National Institute on Drug Abuse (NIDA)Completed
Clinical Trials on Clomid
-
Menoufia Obstetrics and Gynecology GroupCompleted
-
rana alaaeldin aly ibrahim nasrAin Shams UniversityNot yet recruitingPolycystic Ovary Syndrome | Vitamin D Deficiency | Clomiphene Allergy
-
Ain Shams UniversityCompleted
-
Ahmed Fathy Ali Mohamed GhanemCompletedFemale Infertility Associated With Anovulation
-
The Egyptian IVF-ET CenterUnknown
-
Kufa UniversityCompletedPolycystic Ovary SyndromeIraq
-
Neil ChappellNot yet recruitingInfertility | Infertility, FemaleUnited States
-
Mansoura UniversityCompleted
-
Mohamed Sayed AbdelhafezCompletedInfertility | Polycystic Ovarian SyndromeEgypt